NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oragenics Inc. Regains NYSE Compliance, Advances Clinical Trial, and Expands AI Neurology Pipeline
TL;DR
Oragenics regained NYSE compliance and launched an AI collaboration with Receptor.AI to develop neurological therapeutics, positioning investors for potential first-mover advantage in brain-targeted treatments.
Oragenics uses proprietary intranasal delivery technology to develop brain-targeted therapeutics, with ONP-002 advancing to Phase IIa trials and AI-driven pipeline expansion for neurological conditions.
Oragenics' brain-targeted therapeutics platform aims to transform neurological care for concussion, Parkinson's, and Alzheimer's patients through non-invasive treatments that improve recovery outcomes worldwide.
Oragenics is pioneering intranasal brain therapeutics using AI to target conditions from concussion to PTSD, creating a neurological platform beyond single-drug development.
Found this article helpful?
Share it with your network and spread the knowledge!
Oragenics has regained full NYSE American compliance and reported major third quarter 2025 progress, including preparations for its first Phase IIa trial of ONP-002 and a strategic collaboration with Receptor.AI to expand its neurological therapeutics pipeline using artificial intelligence.
Regaining NYSE American compliance is significant because it maintains the company's listing status on the exchange, which is crucial for investor confidence, stock liquidity, and continued access to public capital markets.
ONP-002 is Oragenics' lead candidate that is advancing with the goal of becoming the first FDA-approved treatment for concussion, and it's currently preparing for Phase IIa clinical trials.
The company launched a strategic collaboration with Receptor.AI to use artificial intelligence to identify and validate next-generation candidates for conditions such as Parkinson's, Alzheimer's, PTSD, and anxiety.
The company is establishing clinical infrastructure in Australia as part of its preparations for the Phase IIa trial of ONP-002.
Oragenics is developing brain-targeted therapeutics via proprietary intranasal delivery technology that has the potential to enable targeted, non-invasive therapeutics for brain-related conditions.
According to CEO Janet Huffman, 'We're not building a one-drug company—we're building a neurological therapeutics platform,' and they're creating a movement around brain-first recovery that transforms how patients, clinicians, and healthcare systems approach neurological trauma.
The platform technology has the potential to address neurodegenerative diseases, CNS disorders, concussion, and other neurological conditions, including Parkinson's, Alzheimer's, PTSD, and anxiety through their AI collaboration.
The latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN, and the full press release can be viewed at https://ibn.fm/rLGMC.
ONP-002 is preparing for its first-ever Phase IIa clinical trial, representing a significant advancement toward potential FDA approval for concussion treatment.
Curated from InvestorBrandNetwork (IBN)
